Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
shVAMP7 lentivirus
- Development stage
- Preclinical
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral
01
Overview
shVAMP7 lentivirus is a gene therapy construct designed to silence the expression of Vesicle-associated membrane protein 7 (VAMP7) through RNA interference. VAMP7 is a member of the SNARE family that has been identified as an oncogenic driver in esophageal cancer, where it functions as a ferroptosis checkpoint inhibitor and promotes resistance to cisplatin. By delivering short hairpin RNA (shRNA) via a lentiviral vector, this agent targets and degrades VAMP7 mRNA, leading to reduced protein levels. This knockdown attenuates malignant hallmarks such as cell proliferation, migration, and epithelial-mesenchymal transition (EMT), while simultaneously downregulating the GPX4/NRF2 axis to sensitize tumor cells to ferroptosis and apoptosis. Preclinical studies have demonstrated that shVAMP7 lentivirus can synergize with cisplatin to suppress tumor growth in xenograft models.
- Other names
- VAMP7-shRNA lentivirusVAMP-7-shRNA lentivirusVAMP 7-shRNA lentiviruslentiviral shVAMP7VAMP7-silencing lentivirusVAMP-7-silencing lentivirusVAMP 7-silencing lentivirus
02
Targets
VAMP7 (Vesicle-associated membrane protein 7)
Beyond the preview
Go deeper on shVAMP7 lentivirus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on shVAMP7 lentivirus.